NeuroOne® OneRF® Technology Success Story Featured on Fox News
NeuroOne Medical Technologies (Nasdaq: NMTC) announced that its OneRF® Ablation System was featured in a national Fox News article highlighting a successful pediatric epilepsy treatment. The article showcases 17-year-old Clara Fuller, who previously experienced up to 10 seizures nightly due to a rare, medication-resistant epilepsy.
Clara made history as the first pediatric patient treated with NeuroOne's OneRF® technology, which performs minimally invasive radiofrequency ablation of seizure-causing brain tissue. Following the procedure, Clara has become completely seizure-free, enabling her to sleep uninterrupted and resume normal teenage activities.
NeuroOne Medical Technologies (Nasdaq: NMTC) ha annunciato che il suo OneRF® Ablation System è stato presentato in un articolo nazionale di Fox News che evidenzia un trattamento di epilessia pediatrica di successo. L'articolo racconta la storia di Clara Fuller, una ragazza di 17 anni che in precedenza soffriva di fino a 10 crisi notturne a causa di un'epilessia rara e resistente ai farmaci.
Clara ha fatto la storia come la prima paziente pediatrica trattata con la tecnologia OneRF® di NeuroOne, che esegue un'ablazione a radiofrequenza minimamente invasiva del tessuto cerebrale responsabile delle crisi. Dopo l'intervento, Clara è diventata completamente libera da crisi, permettendole di dormire senza interruzioni e riprendere le normali attività da adolescente.
NeuroOne Medical Technologies (Nasdaq: NMTC) anunció que su OneRF® Ablation System fue destacado en un artículo nacional de Fox News que resalta un tratamiento exitoso para la epilepsia pediátrica. El artículo presenta a Clara Fuller, una adolescente de 17 años que anteriormente experimentaba hasta 10 convulsiones nocturnas debido a una epilepsia rara y resistente a los medicamentos.
Clara hizo historia como la primera paciente pediátrica tratada con la tecnología OneRF® de NeuroOne, que realiza una ablación por radiofrecuencia mínimamente invasiva del tejido cerebral que causa las convulsiones. Tras el procedimiento, Clara se ha vuelto completamente libre de convulsiones, lo que le permite dormir sin interrupciones y retomar sus actividades normales de adolescente.
NeuroOne Medical Technologies (Nasdaq: NMTC)는 자사의 OneRF® Ablation System이 성공적인 소아 간질 치료를 다룬 전국적인 폭스 뉴스 기사에 소개되었다고 발표했습니다. 이 기사는 드문 약물 저항성 간질로 인해 매일 밤 최대 10회의 발작을 경험했던 17세 클라라 풀러의 이야기를 보여줍니다.
클라라는 NeuroOne의 OneRF® 기술로 치료받은 첫 번째 소아 환자로 역사에 남았습니다. 이 기술은 발작을 유발하는 뇌 조직을 최소 침습적으로 고주파 절제합니다. 시술 후 클라라는 완전히 발작이 없는 상태가 되어, 방해받지 않고 잠을 잘 수 있고 정상적인 십대 활동을 재개할 수 있게 되었습니다.
NeuroOne Medical Technologies (Nasdaq: NMTC) a annoncé que son OneRF® Ablation System a été présenté dans un article national de Fox News mettant en avant un traitement réussi de l'épilepsie pédiatrique. L'article met en lumière Clara Fuller, une adolescente de 17 ans qui avait auparavant jusqu'à 10 crises par nuit en raison d'une épilepsie rare et résistante aux médicaments.
Clara a marqué l'histoire en tant que première patiente pédiatrique traitée avec la technologie OneRF® de NeuroOne, qui effectue une ablation par radiofréquence peu invasive du tissu cérébral responsable des crises. Suite à l'intervention, Clara est devenue complètement libre de crises, ce qui lui permet de dormir sans interruption et de reprendre des activités normales d'adolescente.
NeuroOne Medical Technologies (Nasdaq: NMTC) gab bekannt, dass ihr OneRF® Ablation System in einem nationalen Artikel von Fox News vorgestellt wurde, der eine erfolgreiche Behandlung von pädiatrischer Epilepsie hervorhebt. Der Artikel zeigt die 17-jährige Clara Fuller, die zuvor bis zu 10 Anfälle pro Nacht aufgrund einer seltenen, medikamentenresistenten Epilepsie hatte.
Clara schrieb Geschichte als die erste pädiatrische Patientin, die mit der OneRF®-Technologie von NeuroOne behandelt wurde, die eine minimal-invasive Radiofrequenzablation des anfallsauslösenden Hirngewebes durchführt. Nach dem Eingriff ist Clara vollständig anfallfrei geworden, was es ihr ermöglicht, ungestört zu schlafen und ihre normalen Aktivitäten als Teenager wieder aufzunehmen.
- First successful pediatric treatment demonstrates clinical efficacy of OneRF® technology
- Complete elimination of seizures in medication-resistant epilepsy case shows strong treatment outcomes
- National media exposure on Fox News increases visibility and credibility
- None.
Pediatric Patient Treated with OneRF® Ablation System Goes From Up to 10 Nightly Seizures to Zero
EDEN PRAIRIE, Minn., April 14, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that its proprietary OneRF® Ablation System was recently featured in a national Fox News article highlighting the successful treatment of a pediatric epilepsy patient.
The article shares the story of 17-year-old Clara Fuller, who previously experienced up to 10 seizures per night due to a rare, medication-resistant form of epilepsy. Clara made history as the first pediatric patient to undergo treatment using NeuroOne’s OneRF® technology, which enables the minimally invasive radiofrequency ablation of seizure-causing brain tissue. Since the procedure, Clara has been completely seizure-free, enjoying uninterrupted sleep and a return to everyday teenage life.
The full article, published April 11, 2025, is available at:
https://www.foxnews.com/tech/teen-goes-from-10-nightly-seizures-zero-brain-implant
“We are honored to have our technology play a role in changing Clara’s life,” said Dave Rosa, CEO of NeuroOne. “This feature reinforces the benefits of the OneRF® platform and our commitment to advancing minimally invasive solutions for patients living with debilitating neurological conditions.”
To learn more about NeuroOne and its groundbreaking work in epilepsy treatment, as well as the potential for our OneRF® platform to be used in drug delivery and pain management, please visit nmtc1.com.
About NeuroOne
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit nmtc1.com.
Forward Looking Statements
This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this press release may be a forward–looking statement that reflects NeuroOne’s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words or phrases “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “forecasts,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue, “focused on,” “committed to” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward–looking statements may include statements regarding our business strategy, market size, and potential growth opportunities. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations for the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks related to whether the Company will continue to maintain compliance with all Nasdaq continued listing requirements, risks that our strategic partnerships may not facilitate the commercialization or market acceptance of our technology; whether due to supply chain disruptions, labor shortages or otherwise; risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials; risks related to uncertainties associated with the Company’s capital requirements to achieve its business objectives and ability to raise additional funds: the risk that we may not be able to secure or retain coverage or adequate reimbursement for our technology; uncertainties inherent in the development process of our technology; risks related to changes in regulatory requirements or decisions of regulatory authorities; that we may not have accurately estimated the size and growth potential of the markets for our technology; risks relate to clinical trial patient enrollment and the results of clinical trials; that we may be unable to protect our intellectual property rights; and other risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.
Caution: Federal law restricts this device to sale by or on the order of a physician.
IR Contact
MZ Group – MZ North America
NMTC@mzgroup.us
FAQ
What results did the first pediatric patient achieve with NeuroOne's OneRF® treatment (NMTC)?
How does NeuroOne's OneRF® Ablation System (NMTC) treat epilepsy?
What medical conditions can NeuroOne's OneRF® platform (NMTC) potentially treat?
When was the successful OneRF® pediatric epilepsy case featured on Fox News (NMTC)?
